Indian drugmaker Cipla beats profit view on steady demand for respiratory drugs ReutersOctober 30, 2025 at 4:01 AM 0 Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015. REUTERS/Danish Siddiqui (Reuters) India's Cipla reported a betterthanexpected secondquarter profit on Thursday, driven by steady demand for its respiratory drugs.
- - Indian drugmaker Cipla beats profit view on steady demand for respiratory drugs
ReutersOctober 30, 2025 at 4:01 AM
0
Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015. REUTERS/Danish Siddiqui
(Reuters) -India's Cipla reported a better-than-expected second-quarter profit on Thursday, driven by steady demand for its respiratory drugs.
The country's third-largest drugmaker by sales posted a 3.7% rise in consolidated net profit to 13.51 billion rupees ($153.7 million) in the quarter ended September 30, beating analysts' estimates of 13.47 billion rupees, per data compiled by LSEG.
Total revenue increased 7.6% to 75.89 billion rupees, slightly above expectations of 74.30 billion rupees.
Revenue from India, Cipla's biggest market by sales, climbed 7% to 31.46 billion rupees, led by an 8% climb in sales of respiratory drugs.
The drugmaker said sales in North America stood at $233 million during the quarter, against $237 million in the year-ago period.
India and North America account for three-fourths of the company's total sales.
Last week, rival Dr Reddy's reported a quarterly profit that missed analysts' estimates and a 13% drop in its North America sales.
($1 = 87.8950 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Mrigank Dhaniwala and Nivedita Bhattacharjee)
Source: "AOL Money"
Source: Money
Published: October 30, 2025 at 10:19AM on Source: AB JRNL
#ShowBiz#Sports#Celebrities#Lifestyle
0 Comments